ADIL Stock Price, Adial Pharmaceuticals Quote, Chart

Market Summary

USD1.51+0.10

Delayedas of 17 May 2024, 01:56 pm

7.09%

ADIL Stock Price

View Fullscreen

ADIL RSI Chart

ADIL Valuation

Market Cap

6.0M

Price/Earnings (Trailing)

-0.7

EV/EBITDA

-0.1

Price/Free Cashflow

-0.97

MarketCap/EBT

-0.55

ADIL Price/Sales (Trailing)

ADIL Profitability

Return on Equity

-138.67%

Return on Assets

-126.99%

Free Cashflow Yield

-102.77%

ADIL Fundamentals

ADIL Earnings

Earnings (TTM)

-8.5M

Earnings Growth (Yr)

-122.88%

Earnings Growth (Qtr)

-204.68%

Breaking Down ADIL Revenue

52 Week Range

1.53

(Low)(High)

Last 7 days

-13.3%

Last 30 days

-36.2%

Last 90 days

24.3%

Trailing 12 Months

333.3%

How does ADIL drawdown profile look like?

ADIL Financial Health

Current Ratio

9.48

ADIL Investor Care

Shares Dilution (1Y)

271.13%

Diluted EPS (TTM)

-3.1

Tracking the Latest Insider Buys and Sells of Adial Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 29, 2023	schuyler kevin	bought	1,918	2.74	700	-
May 23, 2023	truluck joseph	acquired	-	-	157,500	chief financial officer
May 23, 2023	stilley william b. iii	acquired	-	-	240,800	-
May 23, 2023	claiborne cary j	acquired	-	-	420,000	chief executive officer
Dec 30, 2022	stilley william b. iii	back to issuer	-	-	-166,667	-
Sep 20, 2022	claiborne cary j	acquired	31,515	0.4202	75,000	chief executive officer
Sep 19, 2022	claiborne cary j	acquired	10,735	0.4294	25,000	chief executive officer
Aug 18, 2022	claiborne cary j	acquired	-	-	1,000,000	chief executive officer
Feb 23, 2022	stilley william b. iii	acquired	-	-	250,000	chief executive officer
Dec 30, 2021	newman james w. jr.	bought	13,600	2.72	5,000	-

Which funds bought or sold ADIL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	added	66.67	3.00	20.00	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-295,740	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	9.23	-1,724	6,151	-%
May 15, 2024	Royal Bank of Canada	reduced	-50.00	-	-	-%
May 14, 2024	Qube Research & Technologies Ltd	unchanged	-	-4.00	11.00	-%
May 13, 2024	UBS Group AG	added	58.09	879	7,616	-%
May 13, 2024	HRT FINANCIAL LP	new	-	47,000	47,000	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	120	25,000	68,000	-%
May 10, 2024	BlackRock Inc.	unchanged	-	-4,049	10,160	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	37.5	-	15.00	-%

Are Funds Buying or Selling ADIL?

Are funds buying ADIL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADIL

No. of Funds

Unveiling Adial Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	166,972	SC 13G
Feb 14, 2022	peikin mark howard	4.4%	904,444	SC 13G/A
Aug 18, 2021	peikin mark howard	6.67%	1,346,741	SC 13G/A
Aug 13, 2021	peikin mark howard	5.52%	1,120,241	SC 13G
Aug 13, 2021	stilley william b. iii	9.38%	2,005,752	SC 13D/A
Feb 16, 2021	armistice capital, llc	4.5%	712,500	SC 13G/A
Feb 08, 2021	stilley william b. iii	11.1%	1,769,363	SC 13D/A
Dec 11, 2020	stilley william b. iii	9.97%	1,513,310	SC 13D/A
Jun 19, 2020	armistice capital, llc	5.0%	712,500	SC 13G
Jun 18, 2020	intracoastal capital, llc	3.4%	470,000	SC 13G

Recent SEC filings of Adial Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
Apr 26, 2024	8-K	Current Report
Apr 23, 2024	424B3	Prospectus Filed
Apr 19, 2024	EFFECT	EFFECT
Apr 18, 2024	424B5	Prospectus Filed
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Apr 12, 2024	S-3	S-3
Apr 01, 2024	10-K	Annual Report
Mar 27, 2024	4	Insider Trading

Peers (Alternatives to Adial Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Adial Pharmaceuticals Inc News

Latest updates

Adial Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	41.1%	6,684	4,737	2,867	3,779	3,902	5,733	7,742	10,923	13,964	7,475	10,446	8,063	8,625	5,491	8,178	9,475	5,941	7,680	9,507	10,687	12,060
Current Assets	66.8%	5,336	3,199	1,135	2,047	2,965	4,780	6,773	9,940	12,965	6,462	7,986	5,590	6,172	5,136	8,172	9,469	5,935	7,673	9,501	10,681	12,053
Cash Equivalents	77.7%	5,025	2,827	316	1,218	2,313	4,002	5,753	9,157	12,689	6,062	7,180	5,210	5,638	4,401	7,365	8,624	4,952	6,777	8,530	10,254	11,394
Net PPE	-	-	-	-	-	48.00	50.00	52.00	54.00	56.00	58.00	62.00	62.00	30.00	-	-	-	-	-	-	-	-
Goodwill	-	-	-	-	-	249	249	249	249	249	249	131	131	131	-	-	-	-	-	-	-	-
Liabilities	-13.8%	563	653	528	462	2,462	2,456	2,333	2,962	3,256	3,967	3,246	3,234	3,008	1,505	-	-	-	-	-	-	-
Current Liabilities	-13.8%	563	653	528	462	1,798	1,791	1,327	1,867	2,171	2,722	1,958	2,213	2,042	1,505	1,093	682	390	539	777	627	329
Shareholder's Equity	49.9%	6,122	4,084	2,339	3,317	1,440	3,276	5,409	7,961	10,707	3,508	7,200	4,829	5,618	3,986	7,085	8,793	5,551	7,141	8,730	10,061	11,731
Retained Earnings	-9.4%	-75,274	-68,797	-66,877	-65,492	-66,580	-63,674	-60,807	-57,698	-53,850	-50,943	-45,100	-40,794	-36,353	-31,519	-28,050	-24,714	-22,903	-20,626	-18,568	-16,852	-14,718
Additional Paid-In Capital	11.7%	81,392	72,880	69,216	68,809	67,992	66,950	66,190	65,634	64,535	54,430	52,292	45,605	41,954	35,491	35,121	33,494	28,444	27,757	27,288	26,903	26,439
Shares Outstanding	143.8%	4,055	1,663	1,218	1,198	1,141	1,067	1,074	1,034	926	838	715	674	691	576	-	-	-	-	-	-	-
Float	-	-	-	-	5,385	-	-	-	31,265	-	-	-	40,504	-	-	-	14,669	-	-	-	12,307	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-33.0%	-1,626	-1,222	-1,390	-1,894	-2,298	-1,750	-3,403	-3,534	-2,496	-2,373	-3,529	-3,203	-2,843	-2,614	-2,208	-985	-1,825	-1,752	-1,724	-1,140	-1,721
Share Based Compensation	-19.5%	226	281	268	738	460	734	557	1,100	984	884	1,189	843	1,325	370	678	395	571	469	385	464	284
Cashflow From Investing	-100.0%	-	350	350	-	-	-	-	-	-	-	-	-33.73	-286*	-	-	-	-	-	-	-	-
Cashflow From Financing	13.0%	3,824	3,384	139	58*	610	-	-	2.00	9,124	1,255	5,500	2,809	4,081	-	950	-	-	109*	178*	26*	9,246

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ADIL Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Expenses:
Research and development expenses	$ 454,278	$ 365,616
General and administrative expenses	1,390,744	1,903,159
Total Operating Expenses	1,845,022	2,268,775
Loss From Operations	(1,845,022)	(2,268,775)
Other Income (Expense)
Interest income	22,801	28,892
Inducement expense	(4,464,427)
Losses from equity method investment	(189,870)
Other expenses	(42)
Total other income (expense)	(4,631,538)	28,892
Loss Before Provision For Income Taxes	(6,476,560)	(2,239,883)
Provision for income taxes
Loss from Continuing Operations	(6,476,560)	(2,239,883)
Loss from discontinued operations, net of taxes		(665,953)
Net Loss	$ (6,476,560)	$ (2,905,836)
Loss per share from continuing operations, basic (in Dollars per share)	$ (2.19)	$ (2.12)
Income (Loss) per share from discontinued operations, basic (in Dollars per share)		(0.63)
Net loss per share, basic (in Dollars per share)	$ (2.19)	$ (2.75)
Weighted average shares, basic (in Shares)	2,953,913	1,058,542

ADIL Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 5,025,110	$ 2,827,082
Prepaid research and development	36,000
Prepaid expenses and other current assets	275,356	371,597
Total Current Assets	5,336,466	3,198,679
Intangible assets, net	3,772	3,913
Equity method investment	1,344,143	1,534,013
Total Assets	6,684,381	4,736,605
Current Liabilities:
Accounts payable	177,468	103,325
Accounts payable, related party		24,062
Accrued expenses	375,263	477,747
Accrued expenses, related party	10,000	47,942
Total Current Liabilities	562,731	653,076
Total Liabilities	562,731	653,076
Commitments and contingencies – see Note 9
Stockholders’ Equity
Preferred Stock, 5,000,000 shares authorized with a par value of $0.001 per share, 0 shares outstanding at March 31, 2024 and December 31, 2023
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 4,054,861 and 1,663,421 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	4,054	1,663
Additional paid in capital	81,392,028	72,879,738
Accumulated deficit	(75,274,432)	(68,797,872)
Total Stockholders’ Equity	6,121,650	4,083,529
Total Liabilities and Stockholders’ Equity	$ 6,684,381	$ 4,736,605

About Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

CEO	Mr. Cary John Claiborne MBA
WEBSITE	adialpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	16

Adial Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Adial Pharmaceuticals Inc? What does ADIL stand for in stocks?

ADIL is the stock ticker symbol of Adial Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adial Pharmaceuticals Inc (ADIL)?

As of Thu May 16 2024, market cap of Adial Pharmaceuticals Inc is 5.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADIL stock?

You can check ADIL's fair value in chart for subscribers.

What is the fair value of ADIL stock?

You can check ADIL's fair value in chart for subscribers. The fair value of Adial Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adial Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADIL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adial Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ADIL is over valued or under valued. Whether Adial Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Adial Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADIL.